Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant

Redfield, RR; Jordan, SC; Busque, S; Vincenti, F; Woodle, ES; Desai, N; Reed, EF; Tremblay, S; Zachary, AA; Vo, AA; Formica, R; Schindler, T; Tran, H; Looney, C; Jamois, C; Green, C; Morimoto, A; Rajwanshi, R; Schroeder, A; Cascino, MD; Brunetta, P;

Redfield, RR (reprint author), Univ Wisconsin, Madison, WI 53706 USA.

AMERICAN JOURNAL OF TRANSPLANTATION, 2019; 19 (11): 3035

Abstract

The limited effectiveness of rituximab plus intravenous immunoglobulin (IVIG) in desensitization may be due to incomplete B cell depletion. Obinutuzum......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索